Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

Progression-Free Survival Improves With Bevacizumab Treatment Among Lung Cancer Patients: Presented at ESMO By Ed Susman STOCKHOLM, Sweden -- September 16, 2008 -- Use of the targeted agent bevacizumab on top of a background regimen of cisplatin and gemcitabine results in a statistically significant increase in progression-free survival in patients with non-small-cell lung cancer patients, according to research presented here at the 33rd European Society for Medical Oncology Congress (ESMO). In a late-breaker symposium on September 15, Christian Manegold, MD, Heidelberg University, Mannheim, Germany, said that progression-free survival in the Avastin in Lung Cancer (AVAIL) trial was 6.2 months in the placebo arm, 6.8 months with bevacizumab 7.5 mg/kg (P = .0003), and 6.6 months with 15 mg/kg dose of the drug (P = .0456). The trial recruited 1,050 patients with previously untreated stage IIIB or IV non-squamous-cell, non-small-cell lung cancer. Patients who had recurrent disease were also included. Dr. Manegold reported on 347 patients assigned to placebo, 345 to IV bevacizumab 7.5 mg/kg every 3 weeks, and 351 patients to IV bevacizumab 15 mg/kg every 3 weeks. He noted that overall survival was not significantly different between the placebo arm and either bevacizumab arm. He suggested that the study design, which allowed crossover to other lines of therapy after disease progression, could have diluted the possibility of finding a benefit in overall survival. "Overall survival was greater than 13 months in all arms of the study," he said "That is the longest overall survival ever reported in patients with advanced non-small-cell lung cancer," he said. After 30 months of treatment, median overall survival among patients in the bevacizumab 7.5 mg/kg arm was 13.6 months (P = .42), 13.4 months for patients on bevacizumab 15 mg/kg (P = .76), and 13.1 months for patients treated with placebo. All patients received background medication of the combination of cisplatin and gemcitabine. Funding for the AVAIL study was provided by F. Hoffman-LaRoche Ltd. [Presentation title: (AVAIL): A Phase III Randomised Study of First-Line Bevacizumab Combined With Cisplatin/Gemcitabine in Patients With Advanced or Recurrent Non-squamous, Non-Small-Cell-Lung Cancer. Abstract LBA1] E-mail this page to a friend or colleague! To print, use this version